… ProQR Analyst Event The live and archived webcast will be … - 17:00 - Qui, 18/11/2021 - 19:00 During this webcast ProQR leadership will highlight key advancements from its …
… ProQR Therapeutics Virtual R&D Event 2023 ProQR will host a virtual R&D event on Wednesday, March 29, … under “Events” in the “Investors & Media” section of ProQR’s website at www.proqr.com/events . The presentation is …
… ProQR Investor/Analyst Webcast: Lilly Partnership Expansion and Axiomer Overview ProQR Management will host an investor conference call and … the recently announced partnership expansion with Lilly. ProQR will host the call on December 22, 2022, at 8:15am …
… ProQR Top-line results Phase 1/2 trial of sepofarsen in LCA10 patients ProQR presents Positive Top-Line Results from the Phase 1/2 … link . Qui, 10/10/2019 - 08:00 - Qui, 10/10/2019 - 09:00 ProQR presents Positive Top-Line Results from the Phase 1/2 …
… ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology LEIDEN, the Netherlands, Jan. 08, … fibrosis targets,” said Daniel A. de Boer, CEO of ProQR. “We look forward to working closely with the team at …
… ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets Agreement … FERRAND, France, Aug. 01, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company …
… ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day LEIDEN, … in non-core therapeutic areas and non-rare diseases. “The ‘ProQR Vision 2023’ strategy presents a clear path for ProQR …
… European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10 Access … vision with sepofarsen,” stated Daniel A. de Boer, CEO of ProQR. “Looking ahead, our goal is for sepofarsen to reach …
… ProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives … Orphan Drug Designation from FDA and EMA Key Updates ProQR’s drug candidate QRX-421 for Usher syndrome receives …